Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Guerbet SA receives FDA approval for new manufacturing plant for Lipiodol injection


Wednesday, 19 Feb 2014 02:00pm EST 

Guerbet SA:Receives approval from the U.S. Food and Drug Administration (FDA) for a new manufacturing plant for Lipiodol (ethiodized oil) Injection, in Montreal, Canada.FDA approval provides clinicians with additional resource for patient care management.Says it has acquired the Ethiodol NDA effective May 7, 2010 and since then has been working with the FDA to resume manufacturing of Ethiodol to ensure continued availability for the U.S. patients. 

Company Quote

34.2
0.35 +1.03%
11:35am EDT